IL-17 Inhibition in Spondyloarthritis: A Targeted Approach in Psoriatic Arthritis

Prof Philip Mease introduced psoriatic arthritis (PsA) with a particular emphasis on disease symptoms and an update on the status of current disease management. Erik Lubberts described the interleukin (IL)-17 pathway and its role in the pathogenesis of PsA. Prof Iain McInnes reviewed the clinical evidence for the efficacy of IL-17 inhibition in PsA. Prof Désirée van der Heijde brought the symposium to a close with a presentation on the clinical impact of joint structural damage and strategies for its prevention in PsA.